TABLE 3.
Comparison of clinical and pathologic characters between bland thrombus (BT) patients and non‐BT patients
| Non‐BT (n = 102) | BT patients (n = 21) | P value | |
|---|---|---|---|
| Gender, n (%) | 1.000 | ||
| Male | 76 (74.5%) | 16 (76.2%) | |
| Female | 26 (25.5%) | 5 (23.8%) | |
| Age, y, mean ± SD | 58.56 ± 10.56 | 59.00 ± 13.89 | .870 |
| BMI, kg/m2, mean ± SD | 23.56 ± 4.00 | 23.93 ± 3.68 | .696 |
| Side, n (%) | .340 | ||
| Left | 41 (40.2%) | 8 (38.1%) | |
| Right | 61 (59.8%) | 13 (61.9%) | |
| ASA grade, n (%) | .335 | ||
| 1 | 8 (7.8%) | 0 (0%) | |
| 2 | 81 (79.4%) | 12 (57.1%) | |
| 3 | 13 (12.7%) | 9 (42.9%) | |
| Clinical symptoms, n (%) | .126 | ||
| No clinical symptoms | 29 (28.4%) | 3 (14.3%) | |
| Local symptoms | 42 (41.2%) | 10 (47.7%) | |
| Systemic symptoms | 15 (14.7%) | 2 (9.5%) | |
| Both | 16 (15.7%) | 6 (28.5%) | |
| Clinical N stage, n (%) | .336 | ||
| cN0 | 48 (47.1%) | 7 (33.3%) | |
| cN1 | 54 (52.9%) | 14 (66.7%) | |
| Clinical M stage, n (%) | |||
| cM0 | 70 (68.6%) | 14 (66.7%) | .304 |
| cM1 | 32 (31.4%) | 7 (33.3%) | |
| Mayo classification, n (%) | <.001 | ||
| 0 | 28 (27.5%) | 0 (0%) | |
| I | 34 (33.3%) | 1 (4.8%) | |
| II | 24 (23.5%) | 10 (47.6%) | |
| III | 9 (8.8%) | 5 (23.8%) | |
| IV | 7 (6.9%) | 5 (23.8%) | |
| Hemoglobin, g/L, mean ± SD | 122.89 ± 23.76 | 112.38 ± 19.44 | .060 |
| Platelet count, ×109/L, mean ± SD | 245.34 ± 100.82 | 230.00 ± 73.81 | .510 |
| Serum calcium, mg/dL, mean ± SD | 8.71 ± 0.81 | 8.55 ± 0.47 | .405 |
| Albumin, g/L, mean ± SD | 38.29 ± 5.88 | 38.32 ± 5.67 | .982 |
| Alkaline phosphatase, U/L, mean ± SD | 93.46 ± 47.35 | 103.43 ± 60.28 | .404 |
| Preoperative serum creatinine, µmol/L, mean ± SD | 97.88 ± 56.98 | 103.71 ± 27.14 | .648 |
| Tumor diameter, cm, mean ± SD | 8.94 ± 3.50 | 7.64 ± 2.84 | .113 |
| Maximum width of VTT, mm, mean ± SD | 20.28 ± 8.94 | 32.29 ± 7.01 | <.001 |
| The width of VTT at the entrance of the renal vein, mm, mean ± SD | 17.86 ± 6.74 | 26.99 ± 4.47 | <.001 |
| Surgical approach, n (%) | .006 | ||
| Laparoscope | 54 (52.9%) | 4 (19.0%) | |
| Open | 48 (47.1%) | 17 (81.0%) | |
| IVC transverse resection, n (%) | .001 | ||
| No | 92 (90.2%) | 9 (42.9%) | |
| Yes | 10 (9.8%) | 12 (57.1%) | |
| Operative time, min, mean ± SD | 314.86 ± 123.00 | 416.76 ± 103.61 | .001 |
| Surgical blood loss, mL, mean ± SD | 1090.98 ± 1395.21 | 2738.10 ± 2238.41 | .004 |
| Red blood cell transfusion, mL, mean ± SD | 624.51 ± 926.87 | 1933.33 ± 2036.99 | .009 |
| Plasma transfusion, mL, mean ± SD | 171.57 ± 390.07 | 619.05 ± 831.64 | .025 |
| Pathology type, n (%) | .747 | ||
| Clear cell RCC | 86 (84.3%) | 17 (81.0%) | |
| Non‐clear cell RCC | 16 (15.7%) | 4 (19.0%) | |
| Sarcomatoid differentiation, n (%) | 18 (17.6%) | 4 (19.0%) | 1.000 |
| Serum creatinine one week after operation, µmol/L, mean ± SD | 113.13 ± 102.98 | 167.62 ± 203.73 | .245 |
| Postoperative complication, n (%) | 28 (27.5%) | 15 (71.4%) | .011 |
| Postoperative adjuvant targeted therapy, n (%) | 60 (58.8%) | 11 (52.4%) | .814 |